

Iacopo Petrini

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6105445/publications.pdf>

Version: 2024-02-01

86
papers

2,742
citations

218662

26
h-index

189881

50
g-index

91
all docs

91
docs citations

91
times ranked

4174
citing authors

#	ARTICLE	IF	CITATIONS
1	PTEN Expression and KRAS Mutations on Primary Tumors and Metastases in the Prediction of Benefit From Cetuximab Plus Irinotecan for Patients With Metastatic Colorectal Cancer. <i>Journal of Clinical Oncology</i> , 2009, 27, 2622-2629.	1.6	402
2	A specific missense mutation in GTF2I occurs at high frequency in thymic epithelial tumors. <i>Nature Genetics</i> , 2014, 46, 844-849.	21.4	208
3	PD-L1 mRNA expression in plasma-derived exosomes is associated with response to anti-PD-1 antibodies in melanoma and NSCLC. <i>British Journal of Cancer</i> , 2018, 118, 820-824.	6.4	190
4	Thymic Malignancies: From Clinical Management to Targeted Therapies. <i>Journal of Clinical Oncology</i> , 2011, 29, 4820-4827.	1.6	123
5	MicroRNA Expression and Clinical Outcomes in Patients Treated with Adjuvant Chemotherapy after Complete Resection of Non-Small Cell Lung Carcinoma. <i>Cancer Research</i> , 2010, 70, 8288-8298.	0.9	121
6	Mutations of epigenetic regulatory genes are common in thymic carcinomas. <i>Scientific Reports</i> , 2014, 4, 7336.	3.3	109
7	The mitochondrial citrate carrier, SLC25A1, drives stemness and therapy resistance in non-small cell lung cancer. <i>Cell Death and Differentiation</i> , 2018, 25, 1239-1258.	11.2	81
8	Contribution of KRAS mutations and c.2369C > T (p.T790M) EGFR to acquired resistance to EGFR-TKIs in EGFR mutant NSCLC: a study on circulating tumor DNA. <i>Oncotarget</i> , 2017, 8, 13611-13619.	1.8	81
9	Copy number aberrations of BCL2 and CDKN2A/B identified by array-CGH in thymic epithelial tumors. <i>Cell Death and Disease</i> , 2012, 3, e351-e351.	6.3	63
10	Understanding the Mechanisms of Resistance in EGFR-Positive NSCLC: From Tissue to Liquid Biopsy to Guide Treatment Strategy. <i>International Journal of Molecular Sciences</i> , 2019, 20, 3951.	4.1	62
11	Expression and Mutational Status of c-kit in Thymic Epithelial Tumors. <i>Journal of Thoracic Oncology</i> , 2010, 5, 1447-1453.	1.1	61
12	Phase II trial of sorafenib in combination with 5-fluorouracil infusion in advanced hepatocellular carcinoma. <i>Cancer Chemotherapy and Pharmacology</i> , 2012, 69, 773-780.	2.3	61
13	Insulin-like growth factor-1 receptor and phosphorylated AKT-serine 473 expression in 132 resected thymomas and thymic carcinomas. <i>Cancer</i> , 2010, 116, 4686-4695.	4.1	59
14	Are MSCs angiogenic cells? New insights on human nestin-positive bone marrow-derived multipotent cells. <i>Frontiers in Cell and Developmental Biology</i> , 2014, 2, 20.	3.7	51
15	Detection of ALK and KRAS Mutations in Circulating Tumor DNA of Patients With Advanced ALK-Positive NSCLC With Disease Progression During Crizotinib Treatment. <i>Clinical Lung Cancer</i> , 2017, 18, 692-697.	2.6	49
16	From the beginning to resistance: Study of plasma monitoring and resistance mechanisms in a cohort of patients treated with osimertinib for advanced T790M-positive NSCLC. <i>Lung Cancer</i> , 2019, 131, 78-85.	2.0	42
17	Implications of KRAS mutations in acquired resistance to treatment in NSCLC. <i>Oncotarget</i> , 2018, 9, 6630-6643.	1.8	42
18	Detecting cell-of-origin and cancer-specific methylation features of cell-free DNA from Nanopore sequencing. <i>Genome Biology</i> , 2022, 23, .	8.8	40

#	ARTICLE	IF	CITATIONS
19	The amount of activating EGFR mutations in circulating cell-free DNA is a marker to monitor osimertinib response. <i>British Journal of Cancer</i> , 2018, 119, 1252-1258.	6.4	39
20	Copy Number Aberrations of Genes Regulating Normal Thymus Development in Thymic Epithelial Tumors. <i>Clinical Cancer Research</i> , 2013, 19, 1960-1971.	7.0	38
21	Best practices for the management of thymic epithelial tumors: A position paper by the Italian collaborative group for ThYmic MalignanciEs (TYME). <i>Cancer Treatment Reviews</i> , 2018, 71, 76-87.	7.7	38
22	Biology of MET: a double life between normal tissue repair and tumor progression. <i>Annals of Translational Medicine</i> , 2015, 3, 82.	1.7	38
23	Reproducibility of the WHO classification of thymomas: Practical implications. <i>Lung Cancer</i> , 2013, 79, 236-241.	2.0	37
24	Systemic Therapy, Clinical Outcomes, and Overall Survival in Locally Advanced or Metastatic Pulmonary Carcinoid: A Brief Report. <i>Journal of Thoracic Oncology</i> , 2014, 9, 414-418.	1.1	33
25	ED-B fibronectin expression is a marker of epithelial-mesenchymal transition in translational oncology. <i>Oncotarget</i> , 2017, 8, 4914-4921.	1.8	32
26	A multicenter phase II study of the combination of oxaliplatin, irinotecan and capecitabine in the first-line treatment of metastatic colorectal cancer. <i>British Journal of Cancer</i> , 2009, 100, 1720-1724.	6.4	30
27	Real-time <i>q</i> PCR and Droplet Digital PCR: two techniques for detection of the <i>JAK2</i> ^{V617F} mutation in Philadelphia ⁻ negative chronic myeloproliferative neoplasms. <i>International Journal of Laboratory Hematology</i> , 2015, 37, 766-773.	1.3	30
28	Whole Genome and Transcriptome Sequencing of a B3 Thymoma. <i>PLoS ONE</i> , 2013, 8, e60572.	2.5	28
29	A multiparametric approach to improve the prediction of response to immunotherapy in patients with metastatic NSCLC. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 1667-1678.	4.2	27
30	Nanopore sequencing from liquid biopsy: analysis of copy number variations from cell-free DNA of lung cancer patients. <i>Molecular Cancer</i> , 2021, 20, 32.	19.2	27
31	The Droplet Digital PCR: A New Valid Molecular Approach for the Assessment of B-RAF V600E Mutation in Hairy Cell Leukemia. <i>Frontiers in Pharmacology</i> , 2016, 7, 363.	3.5	26
32	Integrating Liquid Biopsy and Radiomics to Monitor Clonal Heterogeneity of EGFR-Positive Non-Small Cell Lung Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 593831.	2.8	25
33	Incidence of T790M in Patients With NSCLC Progressed to Gefitinib, Erlotinib, and Afatinib: A Study on Circulating Cell-free DNA. <i>Clinical Lung Cancer</i> , 2020, 21, 232-237.	2.6	24
34	Mesenchymal cells inhibit expansion but not cytotoxicity exerted by gamma δ T cells. <i>European Journal of Clinical Investigation</i> , 2009, 39, 813-818.	3.4	23
35	erbB in NSCLC as a molecular target: current evidences and future directions. <i>ESMO Open</i> , 2020, 5, e000724.	4.5	22
36	Loss of 18q22.3 Involving the Carboxypeptidase of Glutamate-like Gene Is Associated with Poor Prognosis in Resected Pancreatic Cancer. <i>Clinical Cancer Research</i> , 2012, 18, 524-533.	7.0	21

#	ARTICLE	IF	CITATIONS
37	Evaluation of PTEN expression in colorectal cancer (CRC) metastases (mets) and in primary tumors as predictors of activity of cetuximab plus irinotecan treatment. <i>Journal of Clinical Oncology</i> , 2008, 26, 4003-4003.	1.6	21
38	Treatment-driven tumour heterogeneity and drug resistance: Lessons from solid tumours. <i>Cancer Treatment Reviews</i> , 2022, 104, 102340.	7.7	21
39	Impaired function of gamma-delta lymphocytes in melanoma patients. <i>European Journal of Clinical Investigation</i> , 2011, 41, 1186-1194.	3.4	20
40	EGFR-TKIs in non-small-cell lung cancer: focus on clinical pharmacology and mechanisms of resistance. <i>Pharmacogenomics</i> , 2018, 19, 727-740.	1.3	20
41	NUT Rearrangement is Uncommon in Human Thymic Epithelial Tumors. <i>Journal of Thoracic Oncology</i> , 2012, 7, 744-750.	1.1	18
42	Surgical treatment of pleural recurrence of thymoma: is hyperthermic intrathoracic chemotherapy worthwhile?. <i>Interactive Cardiovascular and Thoracic Surgery</i> , 2020, 30, 765-772.	1.1	18
43	Molecular analysis of cell-free circulating DNA for the diagnosis of somatic mutations associated with resistance to tyrosine kinase inhibitors in non-small-cell lung cancer. <i>Expert Review of Molecular Diagnostics</i> , 2014, 14, 453-468.	3.1	17
44	EGFR and AKT1 overexpression are mutually exclusive and associated with a poor survival in resected gastric adenocarcinomas. <i>Cancer Biomarkers</i> , 2018, 21, 731-741.	1.7	16
45	The increase in activating EGFR mutation in plasma is an early biomarker to monitor response to osimertinib: a case report. <i>BMC Cancer</i> , 2019, 19, 410.	2.6	16
46	Thymectomy in Myasthenic Patients With Thymoma: Killing Two Birds With One Stone. <i>Annals of Thoracic Surgery</i> , 2021, 112, 1782-1789.	1.3	16
47	Triplet Combination of Fluoropyrimidines, Oxaliplatin, and Irinotecan in the First-Line Treatment of Metastatic Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2008, 7, 7-14.	2.3	15
48	RELEVANT Trial: Phase II Trial of Ramucirumab, Carboplatin, and Paclitaxel in Previously Untreated Thymic Carcinoma/B3 Thymoma With Area of Carcinoma. <i>Clinical Lung Cancer</i> , 2018, 19, e811-e814.	2.6	15
49	Different \hat{T} clones sustain GVM and GVH effects in multiple myeloma patients after non-myeloablative transplantation. <i>Leukemia Research</i> , 2006, 30, 529-535.	0.8	14
50	Combining liquid biopsy and radiomics for personalized treatment of lung cancer patients. State of the art and new perspectives. <i>Pharmacological Research</i> , 2021, 169, 105643.	7.1	13
51	Patients with NSCLC may display a low ratio of p.T790M vs. activating EGFR mutations in plasma at disease progression: implications for personalised treatment. <i>Oncotarget</i> , 2017, 8, 86056-86065.	1.8	13
52	Third-Line Chemotherapy with Irinotecan plus 5-Fluorouracil in Caucasian Metastatic Gastric Cancer Patients. <i>Oncology</i> , 2016, 91, 311-316.	1.9	11
53	Human adult mesangiogenic progenitor cells reveal an early angiogenic potential, which is lost after mesengenic differentiation. <i>Stem Cell Research and Therapy</i> , 2017, 8, 106.	5.5	11
54	Arsenic trioxide and ascorbic acid interfere with the BCL2 family genes in patients with myelodysplastic syndromes: an ex-vivo study. <i>Journal of Hematology and Oncology</i> , 2012, 5, 53.	17.0	9

#	ARTICLE	IF	CITATIONS
55	GTF2I Mutations Are Common in Thymic Epithelial Tumors But Not in Hematological Malignancies. , 2017, 37, 5459-5462.		9
56	Recent advances in epigenomics in NSCLC: real-time detection and therapeutic implications. Epigenomics, 2016, 8, 1151-1167.	2.1	8
57	Phase II Trial of Maintenance Treatment With IL2 and Zoledronate in Multiple Myeloma After Bone Marrow Transplantation: Biological and Clinical Results. Frontiers in Immunology, 2020, 11, 573156.	4.8	8
58	Hypertermic Intrathoracic Chemotherapy (HITHOC) for thymoma: a narrative review on indications and results. Annals of Translational Medicine, 2021, 9, 957-957.	1.7	8
59	ED-B-Containing Isoform of Fibronectin in Tumor Microenvironment of Thymomas: A Target for a Theragnostic Approach. Cancers, 2022, 14, 2592.	3.7	8
60	Growth Factor Content in Human Sera Affects the Isolation of Mesangiogenic Progenitor Cells (MPCs) from Human Bone Marrow. Frontiers in Cell and Developmental Biology, 2016, 4, 114.	3.7	7
61	Circulating tumor DNA and the future of EGFR-mutant lung cancer treatment. Pharmacogenomics, 2019, 20, 1255-1257.	1.3	7
62	Myelodysplastic syndromes: advantages of a combined cytogenetic and molecular diagnostic workup. Oncotarget, 2017, 8, 79188-79200.	1.8	5
63	Medical treatment of malignant pleural mesothelioma relapses. Journal of Thoracic Disease, 2018, 10, S333-S341.	1.4	4
64	Nanotopography Induced Human Bone Marrow Mesangiogenic Progenitor Cells (MPCs) to Mesenchymal Stromal Cells (MSCs) Transition. Frontiers in Cell and Developmental Biology, 2016, 4, 144.	3.7	2
65	Multiple Resistance Mechanisms to Tyrosine Kinase Inhibitors in EGFR Mutated Lung Adenocarcinoma: A Case Report Harboring EGFR Mutations, MET Amplification, and Squamous Cell Transformation. Frontiers in Oncology, 2021, 11, 674604.	2.8	2
66	Phase II Study of the Combination of Interleukin-2 with Zoledronic Acid As Maintenance Therapy Following Autologous Stem Cell Transplant in Patients with Multiple Myeloma. Blood, 2016, 128, 5697-5697.	1.4	2
67	CD57 and Î³Tâ€œcell receptor expression in nodal metastatic spread of melanoma. European Journal of Clinical Investigation, 2012, 42, 575-576.	3.4	1
68	Stereotactic body radiation therapy for the treatment of pleural metastases in patients with thymoma: a retrospective review of 22 patients. Journal of Thoracic Disease, 2021, 13, 6373-6380.	1.4	1
69	Gtf2I Mutations are Frequent in Thymic Epithelial Tumors. Annals of Oncology, 2014, 25, iv542.	1.2	0
70	2372 Is there a role for palliative gastrectomy in asymptomatic metastatic gastric cancer?. European Journal of Cancer, 2015, 51, S460-S461.	2.8	0
71	Single-centre experience with third-line chemotherapy with irinotecan plus 5-fluorouracil and leucovorin (FOLFIRI) in metastatic gastric cancer patients. Annals of Oncology, 2015, 26, vi99.	1.2	0
72	Palliative gastrectomy in asymptomatic metastatic esophagogastric cancer (EGC): does it make sense?. Annals of Oncology, 2015, 26, vi98.	1.2	0

#	ARTICLE	IF	CITATIONS
73	Tolerability of FOLFOXIRI regimen after surgical resection for pancreatic cancer. <i>Annals of Oncology</i> , 2015, 26, vi105.	1.2	0
74	149 LOW RPS14 EXPRESSION IS FREQUENTLY FOUND IN NON-5Q-MYELODYSPLASTIC SYNDROMES. <i>Leukemia Research</i> , 2015, 39, S75.	0.8	0
75	THU0308â€¦Extensive analysis of T cell receptor gamma (TCRG) gene rearrangements reveals a similar repertoire in eosinophilic granulomatosis with polyangiitis (EGPA) and in hypereosinophilic syndrome (HES). , 2017, , .		0
76	A retrospective analysis of patients (pts) with non-small-cell lung cancer (NSCLC) with uncommon or complex epidermal growth factor receptor (EGFR) mutations treated with tyrosine kinase inhibitors (EGFR-TKIs): clinical features and outcome. <i>Annals of Oncology</i> , 2017, 28, vi56.	1.2	0
77	Abstract 2995: MicroRNA expression and outcome of adjuvant chemotherapy in patients with completely resected non-small cell lung cancer: International Adjuvant Lung Cancer Trial Biologic Program (IALT-Bio). , 2010, , .		0
78	Abstract LB-314: Array comparative genomic hybridization of thymic epithelial tumors identifies loss of CDKN2A as a prognostic factor and BCL2 family members as targets for therapy. , 2011, , .		0
79	Array-based comparative genomic hybridization analysis to identify prognostic markers for resected pancreatic cancer.. <i>Journal of Clinical Oncology</i> , 2011, 29, 4097-4097.	1.6	0
80	Association of KRAS mutations in cell-free circulating tumor DNA with occurrence of resistance to TKIs in NSCLC.. <i>Journal of Clinical Oncology</i> , 2014, 32, 11056-11056.	1.6	0
81	Comparison of Real-Time PCR and Droplet Digital PCR for the Determination of JAK2V617F Mutation in Ph ⁻ Negative Myeloproliferative Neoplasms. <i>Blood</i> , 2014, 124, 5548-5548.	1.4	0
82	Myelodysplastic Syndromes: A Multidisciplinary Integrated Diagnostic Work-up for Patients' Risk Stratification. <i>Blood</i> , 2014, 124, 5579-5579.	1.4	0
83	KRAS mutations as potential mechanism of crizotinib acquired resistance: a study on circulating tumor DNA.. <i>Journal of Clinical Oncology</i> , 2016, 34, e20526-e20526.	1.6	0
84	Association of PD-L1 mRNA levels in plasma-derived exosomes with response to nivolumab and pembrolizumab in melanoma and NSCLC.. <i>Journal of Clinical Oncology</i> , 2018, 36, 210-210.	1.6	0
85	Integrating liquid biopsy with advanced imaging analysis to improve the prediction of response to immunotherapy in patients with NSCLC.. <i>Journal of Clinical Oncology</i> , 2019, 37, e14054-e14054.	1.6	0
86	Progression free survival and time to local failure after radiosurgery of pleural metastases in twenty-two patients with thymomas.. <i>Journal of Clinical Oncology</i> , 2019, 37, 8565-8565.	1.6	0